Dehaier Medical Wins Medical Equipment Procurement Bid for Shanxi Province Project
19 December 2013 - 1:00AM
Dehaier Medical Systems Ltd. (Nasdaq:DHRM)
("Dehaier" or the "Company"), an emerging leader in the
development, assembly, marketing and sale of medical devices and
homecare medical products in China, announced today that it has
successfully bid on a large-scale medical equipment procurement
valued at approximately $600,000 (RMB 3.7 million). Dehaier's bid
to provide Cardiac Color Doppler Ultrasonic Diagnostic Apparatus
medical equipment was its successful bid with the Beijing Kanglian
Medical Company. Under the bid, Dehaier will provide medical
equipment to rural hospitals and clinics in Shanxi Province under
China's New Rural Infrastructure Project. The Project is supported
by the China Development Bank, one of China's three national policy
banks.
"State-level medical device procurement is one of our strategic
foci," Mr. Ping Chen, CEO and chairman of Dehaier Medical said.
"Meanwhile, we will continue to maintain our traditional medical
business, and promote growth in our sleep apnea and oxygen therapy
business. We believe these goals are key to our success over the
near term."
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the
development, assembly, marketing and sale of medical products in
China, including respiratory and oxygen homecare medical products.
The company develops and assembles its own branded products from
third-party components. The company also distributes products
designed and manufactured by other companies, including medical
devices and respiratory and oxygen homecare products from IMD
(Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco
(UK), ResMed (Australia), and JMS (Japan). Dehaier's technology is
based on two patents, five pending patents, and proprietary
technology. More information may be found at
www.dehaier.com.cn.
Forward-looking Statements
This news release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, fulfillment of bids and contracts,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in reports filed by the company with the Securities and
Exchange Commission. All such forward-looking statements, whether
written or oral, and whether made by or on behalf of the company,
are expressly qualified by the cautionary statements and any other
cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof.
CONTACT: Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn
Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jul 2023 to Jul 2024